Pharmaceutical News

RSS

UB researchers successfully harness E. coli to generate new forms of antibiotics

Like a dairy farmer tending to a herd of cows to produce milk, researchers are tending to colonies of the bacteria Escherichia coli (E. coli) to produce new forms of antibiotics -- including three that show promise in fighting drug-resistant bacteria.

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

Alliance Principle Ingredients/Neutrical Solutions recalls Galenic Health Ginger in Bentonite

Alliance Principle Ingredients/Neutrical Solutions Inc., in consultation with Health Canada, is recalling the health product Galenic Health Ginger in Bentonite (NPN 80053535) due to unacceptable levels of lead for adolescents and children. The product currently contains levels of lead beyond permitted limits for children, but within acceptable limits for adult dosing.

30 May 2015

Global market for asthma treatment expected to reach $21.7 billion by 2020

Despite generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market for asthma treatment is set to witness moderate growth by the end of the decade.

29 May 2015

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

The U.S. Food and Drug Administration (FDA) has approved Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes, Eli Lilly and Company announced today. Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog.

29 May 2015

PDA extends support to Johnson & Johnson Kilmer Conference on sterility assurance and sterilization

The Parenteral Drug Association (PDA) proudly announces that it will be a supporting organization of the Johnson & Johnson Kilmer Conference on sterility assurance and sterilization in 2016.

29 May 2015

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston.

29 May 2015

Study expands understanding of the production of ET-743 compound

For decades, scientists have known that ET-743, a compound extracted from a marine invertebrate called a mangrove tunicate, can kill cancer cells. The drug has been approved for use in patients in Europe and is in clinical trials in the U.S.

29 May 2015

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly based on a misinterpretation of the outcome of the clinical trials once conducted to demonstrate their efficacy. This was the finding of a study conducted by researchers at the Sahlgrenska Academy.

29 May 2015

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.

29 May 2015

Metformin can reduce risk of open-angle glaucoma in people with diabetes

Taking the medication metformin hydrochloride was associated with reduced risk of developing the sight-threatening disease open-angle glaucoma in people with diabetes, according to a study published online by JAMA Ophthalmology.

29 May 2015

Therapy for genetically-caused emphysema slows progression of lung disease

A landmark clinical study in the Lancet provides convincing evidence that a frequently overlooked therapy for genetically-caused emphysema is effective and slows the progression of lung disease.

29 May 2015

Study shows differences in rates of paracetamol-linked acute liver failure among European countries

A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.

29 May 2015

DigiPath, Euphoria partner to set highest medical marijuana patient safety and education standards

DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.

28 May 2015

Clinical trial suggests HIV patients should start therapy sooner rather than later

Findings from a large-scale clinical trial have shown that people with HIV should start antiretroviral therapy as soon as they have been diagnosed, irrespective of what their CD4+ count is...

28 May 2015

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Helsinn Group, the Swiss Group focused on building quality cancer care, today announces that the European Commission has endorsed the Committee for Medicinal Products for Human Use's Opinion recommending the approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients one month of age and older.

27 May 2015

HUYA Bioscience International named winner of bronze Stevie Award

HUYA Bioscience International has been named the winner of a bronze Stevie Award in the Health Products & Services and Pharmaceuticals category in the second annual Asia-Pacific Stevie Awards.

26 May 2015

UC Davis researchers show feasibility of using statins to treat asthma

Statins continue to show that their benefits extend beyond their original focus of lowering high cholesterol. With the increasing prevalence of asthma, scientists are studying the effects of statins in the lungs.

26 May 2015

Pharmaceutical News

UB researchers successfully harness E. coli to generate new forms of antibiotics

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Alliance Principle Ingredients/Neutrical Solutions recalls Galenic Health Ginger in Bentonite

Global market for asthma treatment expected to reach $21.7 billion by 2020

FDA approves Humalog 200 units/mL KwikPen to improve glycemic control in diabetic patients

PDA extends support to Johnson & Johnson Kilmer Conference on sterility assurance and sterilization

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

Study expands understanding of the production of ET-743 compound

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Metformin can reduce risk of open-angle glaucoma in people with diabetes

Therapy for genetically-caused emphysema slows progression of lung disease

Study shows differences in rates of paracetamol-linked acute liver failure among European countries

DigiPath, Euphoria partner to set highest medical marijuana patient safety and education standards

Clinical trial suggests HIV patients should start therapy sooner rather than later

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

HUYA Bioscience International named winner of bronze Stevie Award

UC Davis researchers show feasibility of using statins to treat asthma

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News